Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Cells|February 3, 2019
Control of the Antitumor Immune Response by Cancer MetabolismCharlotte Domblides, Lydia Lartigue, Benjamin Faustin
Cells|July 4, 2018
Metabolic Stress in the Immune Function of T Cells, Macrophages and Dendritic CellsCharlotte Domblides, Lydia Lartigue, Benjamin Faustin
Cells|February 15, 2022
Influence of the Metabolism on Myeloid Cell Functions in Cancers: Clinical PerspectivesThomas Boyer, Céline Blaye, Nicolas Larmonier, et al.
Bulletin Du Cancer|July 5, 2020
Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAveMarine Gross-Goupil, Charlotte Domblides, Felix Lefort, et al.
Expert Opinion on Emerging Drugs|November 27, 2013
Emerging antiangiogenics for renal cancerCharlotte Domblides, Marine Gross-Goupil, Amandine Quivy, et al.
Frontiers in Immunology|March 21, 2022
Beyond Immunosuppression: The Multifaceted Functions of Tumor-Promoting Myeloid Cells in Breast CancersCéline Blaye, Thomas Boyer, Florent Peyraud, et al.
Bulletin Du Cancer|February 27, 2017
[Crizotinib for ROS1-rearranged non-small cell lung cancer patients]Charlotte Domblides, Martine Antoine, Armelle Lavole, et al.
Immunotherapy|December 21, 2023
Immunotherapy for head and neck squamous cell carcinoma: current status and perspectivesAmaury Daste, Mathieu Larroquette, Nyere Gibson, et al.
Immunotherapy|April 28, 2021
Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapyCharlotte Domblides, Marine Gross-Goupil, Alain Ravaud, et al.
International Journal of Molecular Sciences|October 28, 2023
Hormone Receptor Signaling and Breast Cancer Resistance to Anti-Tumor ImmunityAlexandra Moisand, Mathilde Madéry, Thomas Boyer, et al.
Pageof 6